Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic FibrosisThe New England journal of medicine, 2017-11, Vol.377 (21), p.2024-2035 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709847 ;PMID: 29099333Full text available |
|
2 |
Material Type: Article
|
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delThe New England journal of medicine, 2017-11, Vol.377 (21), p.2013-2023 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709846 ;PMID: 29099344Full text available |
|
3 |
Material Type: Article
|
Blockade of IL-6 Trans signaling attenuates pulmonary fibrosisThe Journal of immunology (1950), 2014-10, Vol.193 (7), p.3755-3768 [Peer Reviewed Journal]Copyright © 2014 by The American Association of Immunologists, Inc. ;Copyright © 2014 by The American Association of Immunologists, Inc. 2014 Copyright © 2014 by The American Association of Immunologists, Inc. ;ISSN: 0022-1767 ;EISSN: 1550-6606 ;DOI: 10.4049/jimmunol.1302470 ;PMID: 25172494Full text available |
|
4 |
Material Type: Article
|
Emerging role of HMGB1 in fibrotic diseasesJournal of cellular and molecular medicine, 2014-12, Vol.18 (12), p.2331-2339 [Peer Reviewed Journal]2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. ;Copyright © 2014 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine ;2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. 2014 ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.12419 ;PMID: 25284457Full text available |
|
5 |
Material Type: Article
|
Cystic fibrosis: a clinical viewCellular and molecular life sciences : CMLS, 2017-01, Vol.74 (1), p.129-140 [Peer Reviewed Journal]Springer International Publishing 2016 ;Cellular and Molecular Life Sciences is a copyright of Springer, 2017. ;ISSN: 1420-682X ;EISSN: 1420-9071 ;DOI: 10.1007/s00018-016-2393-9 ;PMID: 27709245Full text available |
|
6 |
Material Type: Article
|
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D MutationAmerican journal of respiratory and critical care medicine, 2013-06, Vol.187 (11), p.1219-1225 [Peer Reviewed Journal]2014 INIST-CNRS ;Copyright American Thoracic Society Jun 1, 2013 ;Copyright © 2013 by the American Thoracic Society 2013 ;ISSN: 1073-449X ;EISSN: 1535-4970 ;DOI: 10.1164/rccm.201301-0153OC ;PMID: 23590265Full text available |
|
7 |
Material Type: Article
|
Spectrum of Fibrotic Lung DiseasesThe New England journal of medicine, 2020-09, Vol.383 (10), p.958-968 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMra2005230 ;PMID: 32877584Full text available |
|
8 |
Material Type: Article
|
Structure-guided combination therapy to potently improve the function of mutant CFTRsNature medicine, 2018-11, Vol.24 (11), p.1732-1742 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Nov 2018 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-018-0200-x ;PMID: 30297908Full text available |
|
9 |
Material Type: Article
|
A functional CFTR assay using primary cystic fibrosis intestinal organoidsNature medicine, 2013-07, Vol.19 (7), p.939-945 [Peer Reviewed Journal]COPYRIGHT 2013 Nature Publishing Group ;COPYRIGHT 2013 Nature Publishing Group ;Copyright Nature Publishing Group Jul 2013 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/nm.3201 ;PMID: 23727931Full text available |
|
10 |
Material Type: Article
|
Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere lengthThorax, 2021-12, Vol.76 (12), p.1242-1245 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2021-217031 ;PMID: 33927016Full text available |
|
11 |
Material Type: Article
|
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosisCell, 2021-12, Vol.184 (26), p.6243-6261.e27 [Peer Reviewed Journal]2021 ;Copyright © 2021. Published by Elsevier Inc. ;2021 Published by Elsevier Inc. 2021 ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.11.033 ;PMID: 34914922Full text available |
|
12 |
Material Type: Article
|
Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with IvacaftorDigestive diseases and sciences, 2016-01, Vol.61 (1), p.198-207 [Peer Reviewed Journal]Springer Science+Business Media New York 2015 ;COPYRIGHT 2016 Springer ;Springer Science+Business Media New York 2016 ;ISSN: 0163-2116 ;EISSN: 1573-2568 ;DOI: 10.1007/s10620-015-3834-2 ;PMID: 26250833 ;CODEN: DDSCDJFull text available |
|
13 |
Material Type: Article
|
Pulmonary fibrosis: patterns and perpetratorsThe Journal of clinical investigation, 2012-08, Vol.122 (8), p.2756-2762 [Peer Reviewed Journal]COPYRIGHT 2012 American Society for Clinical Investigation ;COPYRIGHT 2012 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Aug 2012 ;Copyright © 2012, American Society for Clinical Investigation 2012 ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci60323 ;PMID: 22850886Full text available |
|
14 |
Material Type: Article
|
Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44The Journal of experimental medicine, 2011-07, Vol.208 (7), p.1459-1471 [Peer Reviewed Journal]2011 Li et al. 2011 ;ISSN: 0022-1007 ;EISSN: 1540-9538 ;DOI: 10.1084/jem.20102510 ;PMID: 21708929Full text available |
|
15 |
Material Type: Article
|
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice GuidelineAmerican journal of respiratory and critical care medicine, 2022-05, Vol.205 (9), p.e18-e47 [Peer Reviewed Journal]Copyright American Thoracic Society May 1, 2022 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1073-449X ;EISSN: 1535-4970 ;DOI: 10.1164/rccm.202202-0399st ;PMID: 35486072Full text available |
|
16 |
Material Type: Article
|
Origins of Cystic Fibrosis Lung DiseaseThe New England journal of medicine, 2015-01, Vol.372 (4), p.351-362 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMra1300109 ;PMID: 25607428Full text available |
|
17 |
Material Type: Article
|
Elexacaftor/Ivacaftor/Tezacaftor: First ApprovalDrugs (New York, N.Y.), 2019-12, Vol.79 (18), p.2001-2007 [Peer Reviewed Journal]Springer Nature Switzerland AG 2019 ;Copyright Springer Nature B.V. Dec 2019 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-019-01233-7 ;PMID: 31784874Full text available |
|
18 |
Material Type: Article
|
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosisPLoS genetics, 2018-11, Vol.14 (11), p.e1007723-e1007723 [Peer Reviewed Journal]COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 Sharma et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Sharma et al 2018 Sharma et al ;ISSN: 1553-7404 ;ISSN: 1553-7390 ;EISSN: 1553-7404 ;DOI: 10.1371/journal.pgen.1007723 ;PMID: 30444886Full text available |
|
19 |
Material Type: Article
|
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosisAmerican journal of respiratory cell and molecular biology, 2015-11, Vol.53 (5), p.585-600 [Peer Reviewed Journal]Copyright American Thoracic Society Nov 2015 ;Copyright © 2015 by the American Thoracic Society 2015 ;ISSN: 1044-1549 ;EISSN: 1535-4989 ;DOI: 10.1165/rcmb.2015-0020tr ;PMID: 26121236Full text available |
|
20 |
Material Type: Article
|
Deubiquitinase-targeting chimeras for targeted protein stabilizationNature chemical biology, 2022-04, Vol.18 (4), p.412-421 [Peer Reviewed Journal]2022. The Author(s), under exclusive licence to Springer Nature America, Inc. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. ;ISSN: 1552-4450 ;EISSN: 1552-4469 ;DOI: 10.1038/s41589-022-00971-2 ;PMID: 35210618Full text available |